Atypical Visible Particles - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Atypical Visible Particles
An industry roundtable on how users and makers can best assess and manage black specks.

Pharmaceutical Technology
Volume 36, Issue 7, pp. 86-88

PharmTech: Because there are no existing guidelines about how to handle these visible particles, the user's discovery of black specks in raw materials can in many cases lead to an entire batch of material being rejected. Currently, how does one distinguish between the normal specks that may be formed during the manufacturing process and potentially harmful foreign contaminants?

Van Meter (IPEC): From an excipient manufacturer point of view, we work very closely with customers to analyze the particles. About 80 to 90% of any particles that I have analyzed that are returned from a customer are off-colored polymer. Unfortunately, when you're dealing with pure white powders, it is common to have these very, very small dark particles, and even though they're very small in number, they do stand out. I understand that they cause alarm; but again, 90% of them are purely the listed polymer.

Schoneker (Colorcon): From an excipient user perspective, we've learned that most companies don't talk to their suppliers about these particles. Instead, all kinds of analyses are done to prove that a charred particle is something it's not. Users then have tons of data and still don't know what to do about the particles and they end up rejecting the batch.

The supplier, however, could probably explain why the particles are there, what they are, and how they control them. For example, a supplier might say, 'If the particles are brown, that's normal and you probably don't have to do a whole lot of analyses unless you have some reason to think it's something else. If the specks are purple, however, you need to go to the next step in analysis.' The missing link here is communication.

PharmTech: When such a batch rejection occurs based on atypical visible particles, that decision affects not only cost but also the supply chain, and potentially can lead to a drug shortage. What are your thoughts on this?

Van Meter (IPEC): Yes, very few particles can cause the rejection of an entire batch of materials. But I'd like to clarify that when we're talking about these particles, we're not talking about something that is pervasive or gross, we're talking about just a very, very few micron-size particles in an entire batch of material. At a customer location, if those are seen at receipt, then the entire batch could be quarantined and shipped back. As an excipient manufacturer, that rejection incurs tremendous cost because the material has already been manufactured and shipped. Then you have to bring the material back and perform an appropriate disposition; there's often no rational thought as to why the material was rejected. Sometimes, the recipient decision is just visual— 'I see black specks; I can't accept this lot.' The alternative is for the user to take a controlled approach to call the material manufacturer, do the appropriate investigation, and release the material.

PharmTech: FDA does not have an official position on this subject yet, but are there any visible particles that are considered acceptable in raw materials today or should everything be ruled out?

Buhse (FDA): As an agency, we want to know that you understand what product you're making, so that you know what is or isn't acceptable.... There are risk-based, science-based decisions that you need to make as the manufacturer of the final drug about what you can tolerate in your incoming raw materials, including the excipients. So if you have particles, we would look to see that you understand what they are. Perhaps it's as simple as having a discussion with your supplier and being able to explain to the agency what the particles are and why they are not a risk to public safety or patient safety, which is our prime concern. Risk management, good science, and always keeping the safety of the patient in mind is what we're looking for.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here